Chinese Multi-provincial Cohort Study-Beijing Project

Cardiovascular Diseases Clinical Trial

— CMCS-Beijing  

Official title:

Chinese Multi-provincial Cohort Study-Beijing Project

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04253054
• Other study ID #: CMCS-Beijing 2020
• Status: Enrolling by invitation
• Start date: September 7, 2020
• Est. completion date: March 2021

Study information

• Verified date: December 2020
• Source: Beijing Institute of Heart, Lung and Blood Vessel Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Chinese Multi-provincial Cohort Study (CMCS)-Beijing project is a sub-study in CMCS participants from Beijing, which intended to investigate the progression and determinants of atherosclerosis and aging related health problems through repeat examinations. Exam 0 to Exam 3 have been conducted during 1992 to 2012. Exam 4 is scheduled in 2020.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 3000
• Est. completion date: March 2021
• Est. primary completion date: March 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 100 Years

Eligibility

Inclusion Criteria:

• Participants from CMCS-Beijing
• sign the informed consent

Exclusion Criteria:

• participanting in clinical trials

Related Conditions & MeSH terms

• Aging Problems
• Cardiovascular Diseases
• Cardiovascular Risk Factor
• Olfaction Disorders
• Sleep
• Smell Disorder

Intervention

Other:
• Cardiovascular risk factors
Different level of cardiovascular risk factors, such as aging, hypertension, diabetes, dyslipidemia, smoke, alcohol drink, obesity and et al, associated with genetics, environments and lifestyles
• Aging related health problems
Aging related health problems

Locations

Country	Name	City	State
China	Beijing Sijiqing Hospital, Beijing	Beijing
China	Peking University Hospital, Beijing	Beijing
China	Peking University Shougang Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All fatal and nonfatal acute coronary and stroke events	Acute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths. Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.	From date of enrollment until the date of first documented event or date of cardiovascular death, whichever came first, assessed at least 5 years
Secondary	New-onset of coronary events	Acute coronary heart disease events included acute myocardial infarction, sudden death, and other coronary deaths.	From date of enrollment until the date of first documented event or date of CHD death, whichever came first, assessed at least 5 years
Secondary	New-onset of stroke	Acute stroke events included subarachnoid hemorrhage, intracerebral hemorrhage, or cerebral infarction.	From date of enrollment until the date of first documented event or date of stroke death, whichever came first, assessed at least 5 years
Secondary	Total death	All cause death	From date of enrollment until date of death from all cause, assessed at least 5 years
Secondary	Cognitive dysfunction	Cognitive dysfunction	From date of enrollment until date of first documented event, assessed at least 5 years
Secondary	Olfactory Disorders	Olfactory Disorders	From date of enrollment until date of first documented event, assessed at least 5 years
Secondary	Valvular disease	Valvular disease	From date of enrollment until the date of first documented event or date of valvular disease death, whichever came first, assessed at least 5 years